

Supporting Information for

A Bottom Up Approach Towards Artificial Oxygenases by Combining Iron Coordination Complexes and Peptides

Olaf Cussó,¹ Michael W. Giuliano,² Xavi Ribas,¹ Scott J. Miller^{3,*} and Miquel Costas^{1,*}

¹ QBIS-CAT Research Group, Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química, Universitat de Girona, Campus Montilivi, Girona E-17071, Catalonia, Spain.

² Department of Chemistry and Biochemistry at the College of Charleston, South Carolina, United States.

³ Department of Chemistry, Yale University, P.O. Box 208107, New Haven, Connecticut 06520-8107, United States.

Contents

Supporting Information for	SI.1
1) Experimental Section	SI.3
1.1) Materials	SI.3
1.2) Instrumentation	SI.3
2) Synthesis of substrates	SI.4
3) Synthesis of peptides by solid phase	SI.6
3.1 Solid phase peptide coupling and Fmoc deprotection protocol	SI.6
4) Catalytic studies	SI.7
4.1. General procedure for epoxidation reaction (Scheme 3 and scheme 4)	SI.7
4.2. General procedure for epoxide isolation (Table 3)	SI.8
4.3. Peptide screening	SI.9
4.4. HRMS spectrum of the catalyst under catalysis conditions	SI.11
4.5. Study of non-linear effects	SI.122
5) Characterization of peptides and epoxides	SI.13
5.1. Mass spectrometry analyses of peptides	SI.13
5.2. Characterization of isolated epoxides	SI.20
References	SI.23
A1) ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of substrates	SI.24
A2) ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of isolated epoxides	SI.26
A3) ^1H NMR spectra of peptides	SI.34
A4) GC spectra of epoxides	SI.58
A5) HPLC spectra of epoxides	SI.60

1) Experimental Section

1.1) Materials

Reagents and solvents used were of commercially available reagent quality unless stated otherwise. Solvents were purchased from SDS and Scharlab. Solvents were purified and dried by passing through an activated alumina purification system (M-Braun SPS-800) or by conventional distillation techniques. For solid-phase peptide synthesis we used a cylindrical vessel with a fritted disc and a removable lid equipped with a magnetic stirrer. The iron complexes were previously reported.¹

1.2) Instrumentation

Oxidation products were identified by comparison of their GC or HPLC retention times with those of independently prepared racemate compounds, and/or by ¹H and ¹³C{¹H}-NMR analyses. IR spectra were taken in a Mattson-Galaxy Satellite FT-IR spectrophotometer using a MKII Golden Gate single reflection ATR system. Elemental analyses were performed using a CHNS-O EA-1108 elemental analyzer from Fisons. NMR spectra were taken on BrukerDPX300 and DPX400 spectrometers using standard conditions (Spectra were taken in CDCl₃ and referenced to either TMS at 0.00 ppm). Electrospray ionization mass spectrometry (ESI-MS) experiments were performed on a Bruker Daltonics Esquire 3000 Spectrometer using a 1 > mM solution of the analyzed compound. High resolution mass spectra (HRMS) were recorded on a Bruker MicroTOF-Q IITM instrument with a ESI source at Serveis Tècnics of the University of Girona (for substrates and isolated epoxides the mass error were 5>ppm, and in the case of peptides were 3>ppm). Samples were introduced into the mass spectrometer ion source by direct infusion through a syringe pump and were externally calibrated using sodium formate. Chromatographic resolution of enantiomers was performed on an Agilent GC-7820-A chromatograph using a CYCLOSIL-B column, Sigma-Aldrich Supelco Astec CHIRALDEX G-TA column. HPLC data were recorded using an Agilent HP1100 chromatograph with CHIRALPAK IA, IB, IC, AS-H, OJ-H, OD-H, and OB-H columns

2) Synthesis of substrates

The following olefins were prepared according to the reported procedures.

(S2) 4-F α -methylstyrene. ^1H NMR data agree with values reported²

Published yield (not reported), obtained yield (72%)

(S3) 3-CF₃ α -methylstyrene. ^1H NMR data agree with values reported³

Published yield (87%), obtained yield (81%)

(S4) 2-Me α -methylstyrene. ^1H NMR data agree with values reported⁴

Published yield (83%), obtained yield (78%)

(S5) 2-F α -methylstyrene. ^1H NMR data agree with values reported⁴

Published yield (88%), obtained yield (72%)

(S6) 2-Cl α -methylstyrene. ^1H NMR data agree with values reported⁵

Published yield (81%), obtained yield (80%)

(S7) 2-Br α -methylstyrene. ^1H NMR data agree with values reported⁶

Published yield (96%), obtained yield (77%)

(S9) 2-Me α -ethylstyrene. ^1H NMR data agree with values reported⁷


Published yield (93%), obtained yield (65%)

(S12) *Cis*- β -ethylstyrene. ^1H NMR data agree with values reported⁸

Published yield (98%), obtained yield (94%)


Substrates **S1** and **S11** are commercially available.

Synthesis of alkenes from ketones (S8 and S10)




Representative procedure.

To a suspension of 2.32 g of methyltriphenylphosphonium bromide (6.34 mmol) in THF (30 mL) was added dropwise a solution of *n*-BuLi (4.4 mL, 1.6 M in hexane, 6.9 mmol) at 0°C during 30 minutes. The white suspension changed to a red solution and was stirred at 0°C for 90 min. The commercially available ketone (1.22 g, 6.22 mmol) was then added and the solution was stirred for 20 min at this temperature and then warmed to 70°C and stirred overnight. Afterward, the reaction was quenched with water (5 mL) and the organic layer separated using a separatory funnel. The aqueous layer was extracted with diethyl ether (3 × 50 mL), dried over MgSO₄, and the solvent was removed under reduced pressure. Finally, purification by flash chromatography over silica (hexane/ethyl acetate 98/2) was performed.



S8, Colorless oil; (44% yield); ¹H-NMR (CDCl₃, 400 MHz, 300K) δ, ppm 7.30 – 7.26 (m, 1H), 7.26 – 7.23 (m, 1H), 7.12 (td, *J* = 7.5, 1.2 Hz, 1H), 7.09 – 7.03 (m, 1H), 5.26 – 5.24 (m, 1H), 5.17 (dd, *J* = 1.5, 0.8 Hz, 1H), 2.56 – 2.46 (m, 2H), 1.08 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.1, 158.6, 146.7, 130.3, 130.2, 130.0, 130.0, 128.6, 128.5, 123.9, 123.8, 115.8, 115.5, 114.4, 114.4, 29.3, 12.7. HRMS(ESI+) *m/z* calculated for C₁₀H₁₁FNa [M+Na]⁺ 173.0737, found 173.0736.



S10, Yellow oil; (62% yield); ¹H-NMR (CDCl₃, 400 MHz, 300K) δ, ppm 8.27 (dt, *J* = 2.3, 1.1 Hz, 1H), 8.15 – 8.10 (m, 1H), 7.74 (ddd, *J* = 7.8, 1.8, 1.1 Hz, 1H), 7.53 – 7.47 (m, 1H), 5.45 – 5.37 (m, 1H), 5.23 (q, *J* = 1.4 Hz, 1H), 2.62 – 2.50 (m, 2H), 1.14 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 148.4, 147.9, 143.2, 132.0, 129.2, 122.1, 120.9, 113.5, 27.8, 12.7. HRMS(ESI+) *m/z* calculated for C₁₀H₁₁NO₂Na [M+Na]⁺ 200.0682, found 200.0677.


3) Synthesis of peptides by solid phase

3.1 Solid phase peptide coupling and Fmoc deprotection protocol

To pre-swollen resin (Chlorotrityl polystyrene resin that has been pre-loaded with L-isoleucine.) (0.35 mmols, ~30 min. in DCM) was added Fmoc-protected amino acid (1.75 mmols, 5 equiv.), HCTU (1.75 mmols, 5 equiv.), 6-Cl-HOBt•H₂O (1.75 mmols, 5 equiv.) with DMF (25 mL), followed by NMM (3.5 mmols, N-methylmorpholine) (10 equiv.). The resin mixture was sealed and mixed for 2 h on a rotary mixer and then drained, washing with a combination of DMF (2 x 20 mL), DCM (2 x 20 mL), the Fmoc-protecting group was removed with two treatments of 20% piperidine in DMF (v/v) (~25 mL) for 20 min. each, then washing with a combination of DMF (2 x 20 mL) and DCM (2 x 20 mL).

Resin was cleaved with a 4:1:1 mixture of DCM: 2,2,2-trifluoroethanol: acetic acid (25 mL), treating for 30-60 min before draining. The resulting solution, along with washes, was concentrated a couple of times with additional toluene.

We used 0.013 mmols in the case of small-scale peptide synthesis




Large-scale peptide purification. Peptide purification was carried out using a Biotage Isolera 1 system on a 30 g C18 column using the following:

Solvent A: 0.1 % formic acid in H₂O


Solvent B: 0.1 % formic acid in acetonitrile

Method: hold at 5 % B for 2 CV, gradient from 5% B to 100 % B over 14 CV, hold at 100 % B for 4 CV, re-equilibrate at 5 % CV for 2 CV.

1 CV ~ 20 mL



Peptide 7. White solid; (180 mg, 88% yield,); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.56 (br, 1H), 7.28-7.13 (m, 5H), 6.54 (br, 1H), 5.57 (br, 1H), 4.70-4.42 (m, 3H), 4.38-4.32 (m, 2H), 4.10 (br, 1H), 3.97 (br, 1H), 3.53-3.49 (m, 1H), 3.00-2.91 (m, 1H), 2.35-2.25 (m, 2H), 2.11-1.88 (m, 4), 1.61-1.45 (m, 3H), 1.41-1.36 (m, 3H), 1.25-1.17 (m, 3H), 0.99-0.90 (m, 6H). $^{13}\text{C NMR}$ (150 MHz, CDCl_3) δ ppm 173.7, 172.1, 171.6, 171.0, 169.2, 156.0, 154.9, 136.8, 129.5, 128.5, 126.8, 80.8, 80.0, 69.4, 59.3, 57.9, 55.3, 53.5, 49.8, 47.3, 40.4, 39.7, 38.7, 37.8, 36.1, 28.1, 25.0, 15.6, 11.6. HRMS(ESI+) m/z calculated for $\text{C}_{30}\text{H}_{44}\text{N}_4\text{O}_8\text{Na}$ $[\text{M}+\text{Na}]^+$ 611.3051, found 611.3046



To peptide 7 (5 mg, 0.008mmols, 1 equiv) was added EDC•HCl (1.1 equiv), HOBT•H₂O (1.1 equiv), and MeOH (300 μL). The resulting solution was allowed to stir 48 h. The solvent was removed under reduced pressure and then it was diluted with DCM and washed with aqueous 0.5 M citric acid, half-saturated brine, and saturated aqueous NaHCO₃. The combined organics were dried over Na₂SO₄, filtered, and concentrated. Transparent oil was obtained, 86 % yield (4.4 mg, 0.007 mmols).

4) Catalytic studies

4.1. General procedure for epoxidation reaction (Scheme 3 and scheme 4)

An acetonitrile solution (0.6 mL) of a given olefin (0.013 mmol, final reaction concentration 0.02 M) and $^{\text{Me}_2\text{N}}\mathbf{1Fe}$ (0.2 mg, 0.26 μmol , 2 mol %, final reaction

concentration 0.43 mM) was prepared in a vial (3 mL) equipped with a stir bar at 0°C. 0.52 μmol (4 mol %) of peptide solution in CH₃CN was added directly to the solution. Then, 27 μL of 0.011M solution of hydrogen peroxide solution 30% (2 equiv.) in CH₃CN was added by syringe pump over a period of 30 min at 0°C. The solution was further stirred at 0 °C for 10 minutes. At this point, the internal standard trimethoxybenzene was added and the solution was filtered through a silica gel plug and basic alumina plug, and the solvent was removed under reduced pressure to afford the epoxide product. To determine the conversion and enantioselectivity, the residue was dissolved in hexanes with a few drops of isopropanol and then was analyzed by HPLC (IC column)

The procedure for **table 2** was the same but at -30°C using a cooled acetonitrile bath

4.2. General procedure for epoxide isolation (Table 3)


An acetonitrile solution (6 mL) of a given olefin (0.460 mmol, final reaction concentration 0.08 M) and **(S,S)^{Me2N}1Fe** (7 mg, 9.2 μmol, 2 mol %, final reaction concentration 1.5 mM) was prepared in a vial (30 mL) equipped with a stir bar and cooled in an acetonitrile frozen bath. 10.8 mg of peptide **7** (18.5 μmol, 4 mol %) was added directly to the solution. Then, 310 μL of 1:9 v:v acetonitrile:hydrogen peroxide solution 70% (2 equiv.) was added by syringe pump over a period of 30 min. The solution was further stirred at -30 °C for 30 minutes. At this point, 15 mL of an aqueous NaHCO₃ saturated solution was added to the mixture. The resultant solution was extracted with DCM (3 x 10 mL). Organic fractions were combined, dried over MgSO₄, filtered through a silica gel plug, and the solvent was removed under reduced pressure to afford the epoxide product. This residue was purified by flash column chromatography over silica gel to obtain the pure epoxide (Hexane/AcOEt : 98/2). Finally, the epoxide product was dissolved in hexane and some drops of isopropanol and the was injected to HPLC

In the case of **S7**, catalyst loading was 8 mol % for **(S,S)^{Me2N}1Fe** and 16 mol% for peptide **7**

4.3. Peptide screening

This screening was performed with non purified peptides, just as they were cleaved from resin.

Table SI.1. Screening of peptides in the epoxidation reaction of α -methylstyrene and $\text{Me}_2\text{N}_1\text{Fe}$ catalyst and hydrogen peroxide



Peptides	$(S,S)^{\text{Me}_2\text{N}_1}\text{Fe}$		$(R,R)^{\text{Me}_2\text{N}_1}\text{Fe}$	
	Conv. (%)	ee (%)	Conv. (%)	ee (%)
peptide 11 (Boc- <i>t</i> -Leu- ^D Pro-Val-Ileu-OH)	81	36	65	36
peptide 12 (Boc-Val- ^D Pro-Val-Ileu-OH)	82	30	70	36
peptide 13 (Boc-Ileu- ^D Pro-Aib-Ileu-OH)	67	44	45	32
peptide 14 (Boc-Val- ^D Pro-Aib-Ileu-OH)	82	36	68	36
peptide 15 (Ac-Phe- ^D Pro-Aib-Ileu-OH)	33	22	54	28
peptide 16 (Fmoc-Phe- ^D Pro-Aib-Ileu-OH)	24	26	32	28
peptide 17 (Z-Phe- ^D Pro-Aib-Ileu-OH)	65	38	58	38
peptide 18 (Boc-Phe- ^D Pro-Dibutgly-Ileu-OH)	72	32	95	35
peptide 19 (Boc-Phe- ^D Pro-Cle-Ileu-OH)	71	38	94	24
peptide 20 (Boc-Phe- ^D Pro-AC6C-Ileu-OH)	91	36	94	38
peptide 21 (Boc-Phe- ^D Pro-Gly-Ileu-OH)	83	40	91	27
peptide 22 (Boc-Phe- ^D Pro-Pro-Ileu-OH)	97	56	95	45
peptide 23 (Boc-Phe-Pro- ^D Pro-Ileu-OH)	83	37	90	28
peptide 24 (Boc-Phe- ^D Pro-Pip-Ileu-OH)	95	46	93	45
peptide 25 (Boc-Phe- ^D Pro-Hyp(Bz)-Ileu-OH)	94	56	89	42
peptide 26 (Boc-Phe- ^D Pro-Hyp(tBu)-Ileu-OH)	95	54	82	46
peptide 27 (Boc-Thr(tBu)- ^D Pro-Aib-Ileu-OH)	81	40	96	34
peptide 28 (Boc-Phe(4-I)- ^D Pro-Aib-Ileu-OH)	85	54	88	37
peptide 29 (Boc-3-(2-pyr)-Ala-- ^D Pro-Aib-Ileu-OH)	64	31	86	36
peptide 30 (Boc-2-Naph- ^D Pro-Aib-Ileu-OH)	85	49	90	37
peptide 31 (Boc- ^D Phe- ^D Pro-Aib-Ileu-OH)	15	30	45	32
peptide 32 (Boc-Bip- ^D Pro-Aib-Ileu-OH)	45	41	57	36
peptide 33 (Boc- ^{5F} Phe- ^D Pro-Aib-Ileu-OH)	60	50	88	54


peptide 34 (Boc-Hfe- ^D Pro-Aib-Ileu-OH)	44	46	60	44
peptide 35 (Boc-Phg- ^D Pro-Aib-Ileu-OH)	38	32	67	36
peptide 36 (Boc-Ala(1-Naph)- ^D Pro-Aib-Ileu-OH)	17	40	40	37
peptide 37 (Boc-2CN-Phe- ^D Pro-Aib-Ileu-OH)	88	52	83	40
peptide 38 (Boc-Tyr(tBu)- ^D Pro-Aib-Ileu-OH)	72	48	87	44
peptide 39 (Boc-Tyr(Bn)- ^D Pro-Aib-Ileu-OH)	87	44	88	42
peptide 40 (Boc-2CN-Phe- ^D Pro-Hyp-Ileu-OH)	95	52	94	46
peptide 41 (Boc-Phe(4-I)- ^D Pro-Hyp-Ileu-OH)	88	52	85	45
peptide 42 (Boc- ^{5F} Phe- ^D Pro-Hyp-Ileu-OH)	88	56	83	52
peptide 43 (NPha-Phe- ^D Pro-Hyp-Ileu-OH)	81	32	72	36
peptide 44 (Boc-Val-Phe- ^D Pro-Hyp-Ileu-OH)	87	34	83	29
peptide 45 (Boc- ^D Val-Phe- ^D Pro-Hyp-Ileu-OH)	92	41	91	42
peptide 46 (Boc-Phe-Phe- ^D Pro-Hyp-Ileu-OH)	73	35	81	36
peptide 47 (Boc- ^D Phe-Phe- ^D Pro-Hyp-Ileu-OH)	85	38	84	40
peptide 7-MeO (Boc-Phe- ^D Pro-Hyp-Ileu-OMe)	-	-	-	-

Unless stated, reaction conditions are ^{Me2N}**1Fe** (2 mol%, 0.43 mM), α -methylstyrene (0.013 mmol, 0.021 M, 1 equiv.), H₂O₂ (2.3 equiv.) and peptide (4 mol %) in CH₃CN (0.6 mL) at 0°C during 30 min. Conversions determined by HPLC with trimethoxybenzene as internal standard. Ee's determined by HPLC (IC column)


4.4. HRMS spectrum of the catalyst under catalysis conditions

Figure SI.1. a) HRMS spectrum obtained during H₂O₂ addition (1 min since beginning of addition) in the catalytic oxidation of **S1** by (S,S')^{Me₂N}Fe in presence of peptide **7** (1 equiv. respect to the catalyst). b) Amplified experimental (top) and simulated (bottom) peaks corresponding to (S,S')-[Fe(CF₃SO₃)(peptide7-H⁺)(^{Me₂N}pdp)]⁺

a)




b)



4.5. Study of non-linear effects

Fig. SI. 2. Demonstration of linear correlation between ee's of catalyst and epoxide in the asymmetric epoxidation of *ortho*-methyl- α -methylstyrene (**S4**)



Reaction conditions are 2 mol%, $\text{Me}_2\text{N}_4\text{Fe}$, peptide (4 mol %), H_2O_2 (2.3 equiv.) and in CH_3CN at 0°C during 30 min. Ee's determined by chiral GC

50:50 represents: 1 mol % of (S,S') enantiomer: 1 mol % of (R,R') enantiomer.

60:40 represents: 1.2 mol % of (S,S') enantiomer: 0.8 mol % of (R,R') enantiomer

70:30 represents: 1.4 mol % of (S,S') enantiomer: 0.6 mol % of (R,R') enantiomer


80:20 represents: 1.6 mol % of (S,S') enantiomer: 0.4 mol % of (R,R') enantiomer

90:10 represents: 1.8 mol % of (S,S') enantiomer: 0.2 mol % of (R,R') enantiomer


100:0 represents: 2 mol % of (S,S') enantiomer: 0 mol % of (R,R') enantiomer

5) Characterization of peptides and epoxides

5.1. Mass spectrometry analyses of peptides



reported by Miller and co-workers ⁹




Chemical Formula: $C_{88}H_{88}N_8O_{13}$


Exact Mass: 1464,65

16.3 mg: 73 % yield

HRMS: Calculated/Observed for $C_{88}H_{88}N_8O_{13}Na^{2+}$ 755.3128/ 755.3110



reported by Miller and co-workers ¹⁰




Chemical Formula: $C_{62}H_{65}N_5O_{11}$

Exact Mass: 1055,47

14.5 mg: 90 % yield

HRMS: Calculated/Observed for $C_{62}H_{65}N_5O_{11}Na$ 1078.4573/ 1078.4549




Chemical Formula: $C_{29}H_{44}N_4O_7$

Exact Mass: 560,32

3.9 mg: 53 % yield

HRMS: Calculated/Observed for $C_{29}H_{44}N_4O_7Na$ 583.3102/ 583.3115




Chemical Formula: $C_{32}H_{42}N_4O_7$

Exact Mass: 594,31

7.3 mg: 94 % yield

HRMS: Calculated/Observed for $C_{32}H_{43}N_4O_7^+$ 617.2946/ 617.2961




Chemical Formula: $C_{30}H_{44}N_4O_8$

Exact Mass: 588,32

180 mg: 88 % yield

HRMS: Calculated/Observed for $C_{30}H_{44}N_4O_8Na^+$ 611.3051/ 611.3046




Chemical Formula: $C_{30}H_{46}N_4O_7$

Exact Mass: 574,34

8.1 mg: 82 % yield

HRMS: Calculated/Observed for $C_{30}H_{46}N_4O_7Na$ 597.3259/ 597.3254




Chemical Formula: $C_{26}H_{46}N_4O_7$

Exact Mass: 526,34

9.1 mg: 92 % yield

HRMS: Calculated/Observed for $C_{26}H_{46}N_4O_7Na$ 549.3259/ 549.3254




Chemical Formula: $C_{25}H_{42}N_4O_7$

Exact Mass: 510,31

5.8 mg: 70 % yield

HRMS: Calculated/Observed for $C_{25}H_{42}N_4O_7Na$ 533.2946/ 533.2941




Chemical Formula: $C_{27}H_{48}N_4O_7$

Exact Mass: 540,35

6.2 mg: 86 % yield

HRMS: Calculated/Observed for $C_{27}H_{48}N_4O_7Na$ 563.3415/ 563.3414




Chemical Formula: $C_{26}H_{46}N_4O_7$

Exact Mass: 526,34

4.5 mg: 66 % yield

HRMS: Calculated/Observed for $C_{26}H_{46}N_4O_7Na$ 549.3259/ 549.3262




Chemical Formula: $C_{26}H_{46}N_4O_7$

Exact Mass: 526,34

4.3 mg: 61 % yield

HRMS: Calculated/Observed for $C_{26}H_{47}N_4O_7^+$ 549.3259/ 549.3260




Chemical Formula: $C_{25}H_{44}N_4O_7$

Exact Mass: 512,32

4.4 mg: 66 % yield

HRMS: Calculated/Observed for $C_{25}H_{44}N_4O_7Na$ 535.3102/ 531.3117

Peptide 15




Chemical Formula: $C_{26}H_{38}N_4O_6$
Exact Mass: 502,28

6.2 mg: 95 % yield

HRMS: Calculated/Observed for $C_{26}H_{38}N_4O_6Na$ 525.2684/ 525.2689

Peptide 16




Chemical Formula: $C_{39}H_{46}N_4O_7$
Exact Mass: 682,34

7.1 mg: 90 % yield

HRMS: Calculated/Observed for $C_{39}H_{46}N_4O_7Na$ 705.3259/ 705.3261

Peptide 17




Chemical Formula: $C_{32}H_{42}N_4O_7$
Exact Mass: 594,31

3.5 mg: 42 % yield

HRMS: Calculated/Observed for $C_{32}H_{42}N_4O_7Na$ 617.2946/ 617.2948

Peptide 18




Chemical Formula: $C_{35}H_{56}N_4O_7$
Exact Mass: 644,41

4.5 mg: 59 % yield

HRMS: Calculated/Observed for $C_{35}H_{56}N_4O_7Na$ 667.4068/ 667.4041

Peptide 19




Chemical Formula: $C_{31}H_{46}N_4O_7$
Exact Mass: 586,34

6.7 mg: 90 % yield

HRMS: Calculated/Observed for $C_{31}H_{46}N_4O_7Na$ 609.3259/ 609.3260


Peptide 20



Chemical Formula: $C_{32}H_{48}N_4O_7$
Exact Mass: 600,35

6 mg: 80 % yield


HRMS: Calculated/Observed for $C_{32}H_{48}N_4O_7Na$ 623.3415/ 623.3426



Chemical Formula: $C_{27}H_{40}N_4O_7$
Exact Mass: 532,29

6.2 mg: 83 % yield


HRMS: Calculated/Observed for $C_{27}H_{40}N_4O_7Na$ 555.2789/
55.2773



Chemical Formula: $C_{30}H_{44}N_4O_7$
Exact Mass: 572,32

4 mg: 54 % yield


HRMS: Calculated/Observed for $C_{30}H_{44}N_4O_7Na$ 595.3102/ 595.3094



Chemical Formula: $C_{30}H_{44}N_4O_7$
Exact Mass: 572,32

6.1 mg: 62 % yield


HRMS: Calculated/Observed for $C_{30}H_{44}N_4O_7Na$ 595.3102/ 595.3111



Chemical Formula: $C_{31}H_{46}N_4O_7$
Exact Mass: 586,34

3.9 mg: 52 % yield


HRMS: Calculated/Observed for $C_{31}H_{46}N_4O_7^+$ 609.3259/ 609.3256



Chemical Formula: $C_{37}H_{50}N_4O_8$
Exact Mass: 678,36

5.4 mg: 73 % yield


HRMS: Calculated/Observed for $C_{37}H_{50}N_4O_8Na$ 701.3521/ 701.3512



Chemical Formula: $C_{34}H_{52}N_4O_8$
Exact Mass: 644,38

4.4 mg: 58 % yield


HRMS: Calculated/Observed for $C_{34}H_{52}N_4O_8Na$ 667.3677/ 667.3667



Chemical Formula: $C_{28}H_{50}N_4O_8$
Exact Mass: 570,36

3.3 mg: 41 % yield


HRMS: Calculated/Observed for $C_{28}H_{50}N_4O_8Na$ 593.3521/ 593.3506



Chemical Formula: $C_{29}H_{43}IN_4O_7$
Exact Mass: 686,22


4.9 mg: 56 % yield

HRMS: Calculated/Observed for $C_{29}H_{43}IN_4O_7Na$ 709.2069/ 709.2058

Peptide 29Chemical Formula: $C_{28}H_{43}N_5O_7$


Exact Mass: 561,32

5.3 mg: 66 % yield

HRMS: Calculated/Observed for $C_{28}H_{43}N_5O_7Na$ 584.3055/
584.3026**Peptide 30**Chemical Formula: $C_{33}H_{46}N_4O_7$


Exact Mass: 610,34

39 mg: 43 % yield

HRMS: Calculated/Observed for $C_{33}H_{46}N_4O_7Na$ 633.3259/ 633.3237**Peptide 31**Chemical Formula: $C_{29}H_{44}N_4O_7$


Exact Mass: 560,32

7.1 mg: 76 % yield

HRMS: Calculated/Observed for $C_{29}H_{44}N_4O_7Na$ 583.3102/
583.3093**Peptide 32**Chemical Formula: $C_{35}H_{48}N_4O_7$


Exact Mass: 636,35

3.4 mg: 46 % yield

HRMS: Calculated/Observed for $C_{35}H_{48}N_4O_7Na$ 659.3415/ 659.3400**Peptide 33**Chemical Formula: $C_{29}H_{39}F_5N_4O_7$


Exact Mass: 650,27

3.6 mg: 51% yield

HRMS: Calculated/Observed for $C_{29}H_{39}F_5N_4O_7Na$ 673.2631/
673.2620**Peptide 34**Chemical Formula: $C_{30}H_{46}N_4O_7$


Exact Mass: 574,34

4.4 mg: 56 % yield

HRMS: Calculated/Observed for $C_{30}H_{46}N_4O_7Na$ 597.3259/ 597.3250**Peptide 35**Chemical Formula: $C_{28}H_{42}N_4O_7$

Exact Mass: 546,31


6.6 mg: 87 % yield

HRMS: Calculated/Observed for $C_{28}H_{42}N_4O_7Na$ 569.2946/ 569.2931**Peptide 36**Chemical Formula: $C_{33}H_{46}N_4O_7$

Exact Mass: 610,34


5.6 mg: 68 % yield

HRMS: Calculated/Observed for $C_{33}H_{46}N_4O_7Na$ 633.3259/ 633.3239

Peptide 37Chemical Formula: $C_{30}H_{43}N_5O_7$


Exact Mass: 585,32

6.6 mg: 77 % yield

HRMS: Calculated/Observed for $C_{30}H_{44}N_5O_7Na_2^+$ 630.2874/
630.2863**Peptide 38**Chemical Formula: $C_{33}H_{52}N_4O_8$


Exact Mass: 632,38

6.5 mg: 79 % yield

HRMS: Calculated/Observed for $C_{33}H_{53}N_4O_8Na$ 655.3677/ 655.3674**Peptide 39**Chemical Formula: $C_{36}H_{50}N_4O_8$


Exact Mass: 666,36

6 mg: 66 % yield

HRMS: Calculated/Observed for $C_{36}H_{50}N_4O_8Na$ 689.3521/
689.3501**Peptide 40**Chemical Formula: $C_{31}H_{43}N_5O_8$


Exact Mass: 613,31

4.9 mg: 62 % yield

HRMS: Calculated/Observed for $C_{31}H_{43}N_5O_8Na$ 636.3004/ 636.3004**Peptide 41**Chemical Formula: $C_{30}H_{43}IN_4O_8$

Exact Mass: 714,21


7.1 mg: 81 % yield

HRMS: Calculated/Observed for $C_{30}H_{43}IN_4O_8Na$
737.2018/ 737.2006**Peptide 42**Chemical Formula: $C_{30}H_{39}F_5N_4O_8$

Exact Mass: 678,27


6.7 mg: 76 % yield

HRMS: Calculated/Observed for $C_{30}H_{39}F_5N_4O_7Na$ 701.2580/ 701.2567




Chemical Formula: $C_{37}H_{40}N_4O_8$
 Exact Mass: 668,28
 5.9 mg: 68 % yield

HRMS: Calculated/Observed for $C_{37}H_{40}N_4O_8Na$ 691.2738/ 691.2712




Chemical Formula: $C_{35}H_{53}N_5O_8$
 Exact Mass: 671,39
 7.2 mg: 83 % yield

HRMS: Calculated/Observed for $C_{35}H_{53}N_5O_8Na$ 694.3786/ 694.3787




Chemical Formula: $C_{35}H_{53}N_5O_8$
 Exact Mass: 671,39
 7.3 mg: 84 % yield

HRMS: Calculated/Observed for $C_{35}H_{53}N_5O_8Na$ 694.3786/ 694.3789




Chemical Formula: $C_{39}H_{53}N_5O_8$
 Exact Mass: 719,39
 6.4 mg: 69 % yield

HRMS: Calculated/Observed for $C_{39}H_{53}N_5O_8Na$ 742.3786/ 742.3787



Chemical Formula: $C_{39}H_{53}N_5O_8$
 Exact Mass: 719,39
 6 mg: 64 % yield


HRMS: Calculated/Observed for $C_{39}H_{53}N_5O_8Na$ 742.3786/ 742.3782




Chemical Formula: $C_{31}H_{46}N_4O_8$
 Exact Mass: 602,33
 4.4 mg: 86% yield

HRMS: Calculated/Observed for $C_{31}H_{46}N_4O_8Na$ 625.3208/ 625.3199.


5.2. Characterization of isolated epoxides



S3, colorless oil; (75% yield, 68% ee); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.62 (s, 1H), 7.54 (t, $J = 9.0$ Hz, 2H), 7.45 (t, $J = 7.8$ Hz, 1H), 3.00 (d, $J = 5.3$ Hz, 1H), 2.78 (d, $J = 5.3$ Hz, 1H), 1.74 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ ppm 142.3, 131.1, 130.9, 130.7, 130.5, 128.8, 128.7, 126.7, 124.9, 124.3, 124.3, 124.3, 124.2, 123.1, 122.2, 122.2, 122.2, 122.1, 121.3, 57.0, 56.3, 21.5. HRMS(ESI+) m/z calculated for $\text{C}_{10}\text{H}_9\text{F}_3\text{ONa}$ $[\text{M}+\text{Na}]^+$ 225.0498, found 225.0493. HPLC-separation conditions: Chiralpack OB-H 25°C, 220 nm, 99.9/0.1 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 8.7 min, r.t.(minor) = 10.2 min




S4, colorless oil; (80% yield, 92% ee); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.38 – 7.34 (m, 1H), 7.18 (t, $J = 6.3$ Hz, 2H), 7.14 (t, $J = 8.0$ Hz, 1H), 2.96 (d, $J = 5.3$ Hz, 1H), 2.82 (d, $J = 5.3$ Hz, 1H), 2.41 (s, 3H), 1.60 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ ppm 139.8, 135.1, 130.0, 127.5, 126.8, 125.8, 58.3, 54.7, 23.49, 19.1. HRMS(ESI+) m/z calculated for $\text{C}_{10}\text{H}_{12}\text{ONa}$ $[\text{M}+\text{Na}]^+$ 171.0780, found 171.0789. Chiral GC analysis with CYCLOSIL-B




S6, colorless oil; (82% yield, 84% ee); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.47 (dd, $J = 7.4, 1.8$ Hz, 1H), 7.32 (dd, $J = 7.7, 1.2$ Hz, 1H), 7.27 – 7.22 (m, 3H), 3.00 (d, $J = 5.1$ Hz, 1H), 2.83 (d, $J = 5.1$ Hz, 1H), 1.65 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ ppm 139.6, 132.2, 129.1, 128.6, 128.4, 126.9, 57.8, 55.1. HRMS(ESI+) m/z calculated for $\text{C}_9\text{H}_9\text{ClONa}$ $[\text{M}+\text{Na}]^+$ 191.0234, found


191.0223. HPLC-separation conditions: Chiralpack IB 25°C, 220nm, 98/2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 4.5 min, r.t.(major) = 4.8 min



S7, yellow oil; (67% yield, 90% ee); $^1\text{H-NMR}$ (CDCl_3 , 400 MHz, 300K) δ , ppm 7.55 – 7.52 (m, 1H), 7.51 – 7.47 (m, 1H), 7.32 (td, $J = 7.5, 1.2$ Hz, 1H), 7.17 (ddd, $J = 8.0, 7.4, 1.8$ Hz, 1H), 3.04 (d, $J = 5.1$ Hz, 1H), 2.86 (d, $J = 5.8$ Hz, 1H), 1.68 (s, 4H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ ppm 141.3, 132.3, 129.1, 128.8, 127.5, 121.7, 59.2, 55.4, 22.7. HRMS(ESI+) m/z calculated for $\text{C}_9\text{H}_9\text{BrONa}$ $[\text{M}+\text{Na}]^+$ 234.9729, found 234.9731. Chiral GC analysis with astec CHIRALDEX G-TA




S8, colorless oil; (88% yield, 90% ee); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.38 (t, $J = 7.5$ Hz, 1H), 7.26 (m, 1H), 7.11 (t, $J = 7.5$ Hz, 1H), 7.04 – 7.00 (m, 1H), 2.99 (d, $J = 5.2$ Hz, 1H), 2.83 – 2.78 (d, $J = 5.2$ Hz, 1H), 2.08 (m, 1H), 1.79 (m, 1H), 0.94 – 0.86 (m, 3H). $^{13}\text{C NMR}$ (150 MHz, CDCl_3) δ ppm 161.1, 159.5, 129.3, 129.2, 128.9, 128.9, 127.4, 127.3, 123.9, 123.9, 115.3, 115.1, 58.9, 53.4, 29.1, 8.9. HRMS(ESI+) m/z calculated for $\text{C}_{10}\text{H}_{11}\text{OFNa}$ $[\text{M}+\text{Na}]^+$ 189.0686, found 189.0681. HPLC-separation conditions: Chiralpack AS-H 25°C, 254nm, 99.6/0.4 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 5.6 min, r.t.(minor) = 5.9 min




S9, colorless oil; (66% yield, 90% ee); $^1\text{H-NMR}$ (CDCl_3 , 600 MHz, 300K) δ , ppm 7.31 (d, $J = 7.2$ Hz, 1H), 7.21 – 7.11 (m, 3H), 3.00 (d, $J = 5.2$ Hz, 1H), 2.78 (d, $J = 5.2$ Hz, 1H), 2.38 (s, 3H), 1.93 (m, 1H), 1.79 (m, 1H), 0.91 (t, $J = 7.5$ Hz, 3H). $^{13}\text{C NMR}$ (150 MHz, CDCl_3) δ ppm 138.4, 135.3, 130.0, 128.0, 127.4, 125.4, 61.6, 53.1, 29.1, 19.1, 9.0. HRMS(ESI+) m/z calculated for $\text{C}_{11}\text{H}_{14}\text{ONa}$ $[\text{M}+\text{Na}]^+$ 185.0937, found 185.0933. HPLC-separation conditions: Chiralpack

OJ-H 25°C, 220nm, 99.8/0.2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 7.8 min,
r.t.(minor) = 8.4 min



S10, colorless oil; (99% yield, 86% ee); ¹H-NMR (CDCl₃, 600 MHz, 300K) δ, ppm 8.23 (s, 1H), 8.13 (d, *J* = 9.4 Hz, 1H), 7.70 (d, *J* = 7.7 Hz, 1H), 7.52 (t, *J* = 8.0 Hz, 1H), 3.04 (d, *J* = 5.1 Hz, 1H), 2.73 (d, *J* = 5.1 Hz, 1H), 2.27 (m, 1H), 1.83 (m, 1H), 0.94 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃) δ ppm 148.4, 142.4, 132.0, 129.4, 122.5, 121.2, 60.2, 55.5, 27.7, 8.8. HRMS(ESI+) *m/z* calculated for C₁₀H₁₁NO₃FNa [M+Na]⁺ 216.0631, found 216.0632. HPLC-separation conditions: Chiralpack IC 25°C, 220nm, 99/1 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 12.7 min, r.t.(major) = 13.2 min




S12, colorless oil; (70% yield, 91% ee); ¹H-NMR (CDCl₃, 400 MHz, 300K) δ, ppm 7.42 – 7.29 (m, 5H), 4.11 (d, *J* = 4.2 Hz, 1H), 3.24 – 3.16 (m, 1H), 1.55 – 1.39 (m, 1H), 1.34 – 1.20 (m, 1H), 0.93 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ ppm 135.7, 128.0, 127.4, 126.5, 60.6, 57.5, 20.2, 10.0. HRMS(ESI+) *m/z* calculated for C₁₀H₁₂ONa [M+Na]⁺ 171.0780, found 171.0784. Chiral GC analysis with CYCLOSIL-B


References

- (1) Cussó, O.; Garcia-Bosch, I.; Ribas, X.; Lloret-Fillol, J.; Costas, M. *J. Am. Chem. Soc.* **2013**, *135*, 14871.
- (2) Liang, Z.; Ju, L.; Xie, Y.; Huang, L.; Zhang, Y. *Chem. Eur. J.* **2012**, *18*, 15816.
- (3) Phan, D. H. T.; Kou, K. G. M.; Dong, V. M. *J. Am. Chem. Soc.* **2010**, *132*, 16354.
- (4) Pratsch, G.; Overman, L. E. *J. Org. Chem.* **2015**, *80*, 11388.
- (5) Bertolotti, M.; Brenna, E.; Crotti, M.; Gatti, F. G.; Monti, D.; Parmeggiani, F.; Santangelo, S. *ChemCatChem.* **2016**, *8*, 577.
- (6) Kim, J.; Li, H. B.; Rosenthal, A. S.; Sang, D.; Shapiro, T. A.; Bachi, M. D.; Posner, G. H. *Tetrahedron* **2006**, *62*, 4120.
- (7) Hornback, J. M.; Barrows, R. D. *J. Org. Chem.* **1982**, *47*, 4285.
- (8) van der Waals, D.; Pettman, A.; Williams, J. M. J. *RSC Adv.* **2014**, *4*, 51845.
- (9) Lichtor, P. A.; Miller, S. J. *Nat. Chem.* **2012**, *4*, 990.
- (10) Lichtor, P. A.; Miller, S. J. *J. Am. Chem. Soc.* **2014**, *136*, 5301.


A1) ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of substrates




^1H -NMR of 2-F-alphaethylstyrene in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of 2-F-alphaethylstyrene in CDCl_3







$^1\text{H-NMR}$ of 3- NO_2 -alphaethylstyrene in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of 3- NO_2 -alphaethylstyrene in CDCl_3




A2) ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of isolated epoxides




^1H -NMR of **S3** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S3** in CDCl_3







$^1\text{H-NMR}$ of **S4** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S4** in CDCl_3







$^1\text{H-NMR}$ of **S6** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S6** in CDCl_3







$^1\text{H-NMR}$ of **S7** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S7** in CDCl_3







$^1\text{H-NMR}$ of **S8** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S8** in CDCl_3







$^1\text{H-NMR}$ of **S9** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S9** in CDCl_3







$^1\text{H-NMR}$ of **S10** in CDCl_3




$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S10** in CDCl_3






$^1\text{H-NMR}$ of **S12** in CDCl_3





$^{13}\text{C}\{^1\text{H}\}$ -NMR of **S12** in CDCl_3




A3) ^1H NMR spectra of peptides



^1H -NMR of peptide 7 in CDCl_3 and two drops of MeOD





$^{13}\text{C}\{^1\text{H}\}$ -NMR of peptide 7 in CDCl_3 and two drops of MeOD





$^1\text{H-NMR}$ of non purified **peptides** in CDCl_3









Peptide 8





Peptide 9





Peptide 10





Peptide 11





Peptide 12





Peptide 13





Peptide 14





Peptide 15







Peptide 16





Peptide 17











Peptide 22





Peptide 23





Peptide 24





Peptide 25





Peptide 26





Peptide 27





Peptide 28





Peptide 29





Peptide 30





Peptide 31





Peptide 32





Peptide 33





Peptide 34





Peptide 35





Peptide 36





Peptide 37





Peptide 38





Peptide 39





Peptide 40





Peptide 41





Peptide 42





Peptide 43





Peptide 44





Peptide 45





Peptide 46




Peptide 47



peptide 7-MeO



A4) GC spectra of epoxides



Rac





Table 2 entry 4









Table 3 entry 3




A5) HPLC spectra of epoxides

HPLC-separation conditions: Chiralpack IC 25°C, 220 nm, 98/2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 5.7 min, r.t.(minor) = 6.1 min




Rac





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	6.007	BV	0.1056	589.17432	86.32866	49.8558
2	6.373	VB	0.1091	592.58350	83.19460	50.1442

Table 2 entry 1




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.715	BV	0.0981	3506.15771	551.81085	82.6699
2	6.079	VB	0.1011	734.99506	111.21644	17.3301

HPLC-separation conditions: Chiralpack IC 25°C, 220 nm, 99.9/0.1 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 10.4 min, r.t.(minor) = 11.3 min





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.953	BV	0.2633	3271.98999	191.50729	49.7036
2	10.667	VB	0.3198	3311.02051	158.42682	50.2964

Table 2 entry 2




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.455	BV	0.2455	4005.81982	246.64026	81.4983
2	11.318	VB	0.2254	909.39874	61.91505	18.5017

HPLC-separation conditions: Chiralpack OB-H 25°C, 220 nm, 99.9/0.1 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 8.7 min, r.t.(minor) = 10.2 min




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.733	BV	0.3581	1.46402e4	637.02472	50.1391
2	9.010	VB	0.4186	1.45590e4	533.17413	49.8609

Table 2 entry 3



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	8.701	VV R	0.3934	1.06244e4	416.74301	83.3828
2	10.205	VV R	0.3946	2117.31421	79.01508	16.6172

HPLC-separation conditions: Chiralpack OD-H 25°C, 254nm, 99.4/0.6 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 5.0 min, r.t.(major) = 5.6 min



Rac






Table 3 entry 1




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.042	BB	0.1195	64.59106	7.89121	7.2430
2	5.648	BB	0.1628	827.18713	74.91674	92.7570

HPLC-separation conditions: Chiralpack IB 25°C, 220nm, 98/2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 4.5 min, r.t.(major) = 4.8 min




Rac

The racemic epoxide was obtained mixing (S,S') and (R,R') catalysts (1/1)



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.182	BV	0.0730	3198.84399	677.94733	54.6530
2	4.515	VV R	0.0761	2654.16479	527.20892	45.3470

Table 3 entry 2




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.512	BV	0.0772	249.62737	49.19366	7.8790
2	4.848	VB	0.0828	2918.64746	542.63934	92.1210

HPLC-separation conditions: Chiralpack AS-H 25°C, 254nm, 99.6/0.4 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 5.6 min, r.t.(minor) = 5.9 min




Rac





Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.874	BV	0.1010	1064.74548	161.30972	46.3207
2	6.185	VV R	0.1192	1233.89160	151.35045	53.6793

Table 3 entry 4



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.574	MM	0.1217	2312.80811	316.79874	94.9260
2	5.946	MM	0.1383	123.62414	14.90095	5.0740


HPLC-separation conditions: Chiralpack OJ-H 25°C, 220nm, 99.8/0.2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 7.8 min, r.t.(minor) = 8.4 min



Rac


Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
3	7.536	BV	0.1400	2886.33130	317.81555	48.9063
4	8.098	VB	0.1500	2955.83423	302.48767	50.0840

Table 3 entry 5




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.825	BV R	0.1372	2784.27295	314.71735	94.9409
2	8.384	VB E	0.1438	148.36496	16.05228	5.0591

HPLC-separation conditions: Chiralpack IC 25°C, 220nm, 99/1 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 12.7 min, r.t.(major) = 13.2 min




Rac




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.273	BV	0.2828	2.49392e4	1367.08350	50.0461
2	15.313	VB	0.3178	2.48932e4	1200.85046	49.9539

Table 3 entry 6




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.695	VV E	0.2086	1298.99988	96.74610	7.4257
2	13.195	VV R	0.2519	1.61943e4	1005.60919	92.5743

HPLC-separation conditions: Chiralpack IC 25°C, 220nm, 98/2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(minor) = 4.9 min, r.t.(major) = 5.3 min




Rac




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.996	VB R	0.0934	3423.52515	559.61566	49.6393
2	5.326	MM	0.1068	3473.28149	541.96600	50.3607

Table 3 entry 7




Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.932	BV	0.0811	336.48401	64.28787	4.6574
2	5.259	MM	0.1022	6888.21533	1123.17126	95.3426

HPLC-separation conditions: Chiralpack IC 25°C, 220nm, 98/2 hexane/*i*-PrOH, 1.0 mL/min; r.t.(major) = 5.6 min, r.t.(minor) = 5.9 min




Rac



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.996	VB R	0.0934	3423.52515	559.61566	49.9207
2	5.326	MM	0.1059	3434.40649	540.71307	50.0793

Table 3 entry 8



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	5.589	MM	0.1148	4344.66309	630.71265	94.7947
2	5.947	MM	0.1187	238.57077	33.48513	5.2053